Mecasermin rinfabate

Mecasermin rinfabate is a recombinant DNA derived, insulin-like growth factor (IGF-1) that is used in the treatment of growth hormone insensitivity syndrome (GHIS). It is a complex of recombinant human IGF-1 and recombinant human IGF-1 binding protein-3 (rhIGFBP-3).

History

Mecasermin rinfabate was developed by Insmed and was approved by the Food and Drug Administration (FDA) in the United States in 2005. It was marketed under the brand name IPLEX. However, due to manufacturing issues, it was withdrawn from the market in 2007.

Mechanism of Action

Mecasermin rinfabate works by replacing the insulin-like growth factor that is lacking in people with GHIS. It binds to the IGF-1 receptor and activates a series of intracellular signals that promote cell growth and survival.

Clinical Use

Mecasermin rinfabate is used in the treatment of GHIS, a condition characterized by short stature and delayed growth due to the body's resistance to growth hormone. It is also being investigated for use in other conditions, such as muscular dystrophy and amyotrophic lateral sclerosis (ALS).

Side Effects

Common side effects of mecasermin rinfabate include hypoglycemia, lipohypertrophy, and tonsillar hypertrophy. Serious side effects can include intracranial hypertension.

See Also

• Insulin-like growth factor
• Growth hormone insensitivity syndrome
• Recombinant DNA

This article is a stub related to pharmacology. You can help WikiMD by expanding it!